Innoviva Inc. is a biopharmaceutical company focused on helping address unmet patient needs by enabling the development and delivery of important medicines. The company’s core business is the management of royalty interests, leveraging deep expertise in biopharmaceutical development, commercialization strategy, and financial stewardship. Through this model, Innoviva participates in the long-term value created by marketed therapies while maintaining a disciplined, asset-focused operating structure.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Innoviva has undertaken research and development (R&D) initiatives focused on developing product candidates through preclinical research and clinical trials, with a reliance on third-party contract manufacturers for raw materials, drug substances, and finished drug products. The company is involved in managing manufacturing vendor relationships and processes internally. As of February 2025, the licensed intellectual property portfolio relating to GIAPREZA included 12 issued US patents, two pending US patent applications, 10 issued foreign patents, and 12 pending foreign patent applications. The company also owned two issued US patents, one pending US patent application, 17 issued foreign patents and three pending foreign patent applications relating to XERAVA. In addition, it also owns two issued US patents, one pending US patent application, eight granted foreign patents and seven pending foreign patent applications that relate to crystalline forms of eravacycline. Innoviva owned four issued US patents, 118 issued foreign patents, two pending foreign patent applications, and one pending priority patent cooperation treaty (PCT) application relating to XACDURO and owned seven issued US patents, 75 issued foreign patents, as well as one pending foreign patent application for Zoliflodacin. In FY2025, the company spent US$30.6 million on R&D, which as a percentage of revenue, stood at 7.4%.